{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:20:09Z","timestamp":1787772009049,"version":"build-2784847793"},"reference-count":262,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>PET\/CT and radioisotope therapy are diagnostic and therapeutic arms of Nuclear Medicine, respectively. With the emergence of better technology, PET\/CT has become an accessible modality. Diagnostic tracers exploring disease-specific targets has led the clinicians to look beyond FDG PET. Moreover, with the emergence of theranostic pairs of radiopharmaceuticals, radioisotope therapy is gradually making it\u2019s way into treatment algorithm of common cancers in India. We therefore would like to discuss in detail the updates in PET\/CT imaging and radionuclide therapy and generate a consensus-driven evidence based document which would guide the practitioners of Oncology.<\/jats:p>","DOI":"10.4103\/ijc.ijc_52_24","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T01:00:06Z","timestamp":1709254806000},"page":"S1-S28","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Tata Memorial Centre Evidence Based Use of Nuclear medicine diagnostic and treatment modalities in cancer"],"prefix":"10.4103","volume":"61","author":[{"given":"Ameya D.","family":"Puranik","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayak","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchismita","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indraja D.","family":"Dev","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Ramchandani","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Uppal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikrant","family":"Bhosale","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Palsapure","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachita","family":"Rungta","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Khatri","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemson","family":"George","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Satamwar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Maske","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archi","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilendu C.","family":"Purandare","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Rangarajan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1200\/JCO.18.01182","article-title":"Multicenter trial of [18F] fluorodeoxyglucose positron emission tomography\/computed tomography staging of head and neck cancer and negative predictive value and surgical impact in the N0 neck:Results From ACRIN 6685","volume":"37","author":"Lowe","year":"2019","journal-title":"J Clin Oncol"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"e217083","DOI":"10.1001\/jamanetworkopen.2021.7083","article-title":"Accuracy of 18-F fluorodeoxyglucose positron emission tomographic\/computed tomographic imaging in primary staging of squamous cell carcinoma of the oral cavity","volume":"4","author":"Linz","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R3-20240828","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.amjoto.2018.10.013","article-title":"Diagnostic accuracy of F-18 FDG PET or PET\/CT for detection of lymph node metastasis in clinically node negative head and neck cancer patients;A systematic review and meta-analysis","volume":"40","author":"Kim","year":"2019","journal-title":"Am J Otolaryngol"},{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/hed.24687","article-title":"Distant metastases in head and neck cancer","volume":"39","author":"Duprez","year":"2017","journal-title":"Head Neck"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00005537-200003000-00012","article-title":"Screening for distant metastases in patients with head and neck cancer","volume":"110","author":"de Bree","year":"2000","journal-title":"Laryngoscope"},{"issue":"(Suppl 1)","key":"R6-20240828","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.14639\/0392-100X-suppl.1-40-2020","article-title":"Metastatic disease in head and neck oncology","volume":"40","author":"Pisani","year":"2020","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"224","DOI":"10.6004\/jnccn.2022.0016","article-title":"NCCN Guidelines\u00ae insights:Head and neck cancers, Version 1.2022","volume":"20","author":"Caudell","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3174\/ajnr.A3494","article-title":"Negative predictive value of surveillance PET\/CT in head and neck squamous cell cancer","volume":"34","author":"McDermott","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"R9-20240828","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2967\/jnumed.107.044792","article-title":"Clinical utility of 18F-FDG PET\/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer","volume":"49","author":"Ong","year":"2008","journal-title":"J Nucl Med"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa1514493","article-title":"PET-CT surveillance versus neck dissection in advanced head and neck cancer","volume":"374","author":"Mehanna","year":"2016","journal-title":"N Engl J Med"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2016.11.009","article-title":"18F-FDG PET\/CT surveillance for the detection of recurrence in patients with head and neck cancer","volume":"72","author":"Kim","year":"2017","journal-title":"Eur J Cancer"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00259-021-05540-8","article-title":"Benefit of [18F]-FDG PET\/CT for treatment-na\u00efve nasopharyngeal carcinoma","volume":"49","author":"Yang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1200\/JCO.2012.46.0816","article-title":"Prospective study of tailoring whole-body dual-modality [18F] fluorodeoxyglucose positron emission tomography\/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging","volume":"31","author":"Tang","year":"2013","journal-title":"J Clin Oncol"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.radonc.2007.11.002","article-title":"FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review","volume":"85","author":"Liu","year":"2007","journal-title":"Radiother Oncol"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association Guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00259-018-4045-9","article-title":"[18F]DOPA PET\/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery","volume":"45","author":"Rasul","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R19-20240828","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/thy.2009.0342","article-title":"Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography\/computed tomography in the follow-up of medullary thyroid carcinoma","volume":"20","author":"Luster","year":"2010","journal-title":"Thyroid"},{"key":"R20-20240828","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12020-012-9671-6","article-title":"Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography:A meta-analysis","volume":"42","author":"Treglia","year":"2012","journal-title":"Endocrine"},{"key":"R21-20240828","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2967\/jnumed.106.036681","article-title":"Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels","volume":"48","author":"Ong","year":"2007","journal-title":"J Nucl Med"},{"key":"R22-20240828","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s004280100494","article-title":"Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy","volume":"439","author":"Papotti","year":"2001","journal-title":"Virchows Arch"},{"key":"R23-20240828","first-page":"362","article-title":"Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma:a systematic review and a meta-analysis","volume":"16","author":"Treglia","year":"2017","journal-title":"Hormones (Athens)"},{"key":"R24-20240828","doi-asserted-by":"crossref","first-page":"324686","DOI":"10.1155\/2012\/324686","article-title":"PET Imaging in recurrent medullary thyroid carcinoma","volume":"2012","author":"Treglia","year":"2012","journal-title":"Int J Mol Imaging"},{"key":"R25-20240828","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00259-015-3058-x","article-title":"Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS):Considerations and challenges towards developing an appropriate roadmap","volume":"42","author":"Basu","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R26-20240828","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/RLU.0b013e31825b2057","article-title":"Prognostic significance of FDG PET\/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels:correlation with clinical and histopathologic characteristics and long-term follow-up data","volume":"37","author":"Vural","year":"2012","journal-title":"Clin Nucl Med"},{"key":"R27-20240828","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1007\/s00259-021-05336-w","article-title":"Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography\/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma","volume":"48","author":"Zhao","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"(Suppl 2)","key":"R28-20240828","first-page":"2371","article-title":"Head-to-head comparison of [68Ga]Ga-DOTA. SA. FAPi versus [18F] F-FDG PET\/CT in radioiodine refractory differentiated thyroid cancer patients","volume":"63","author":"Ballal","year":"2022","journal-title":"J Nucl Med"},{"key":"R29-20240828","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13550-022-00922-x","article-title":"A pilot study of 68 Ga-PSMA-617 PET\/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma","volume":"12","author":"Wang","year":"2022","journal-title":"EJNMMI Res"},{"key":"R30-20240828","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/thy.2019.0450","article-title":"68Ga-DOTA-RGD2 positron emission tomography\/computed tomography in radioiodine refractory thyroid cancer:Prospective comparison of diagnostic accuracy with 18F-FDG positron emission tomography\/computed tomography and evaluation toward potential theranostics","volume":"30","author":"Parihar","year":"2020","journal-title":"Thyroid"},{"key":"R31-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"(Suppl 1)","key":"R32-20240828","doi-asserted-by":"crossref","first-page":"A875","DOI":"10.1210\/jendso\/bvab048.1788","article-title":"Estimabl2:Is there a need for radioiodine ablation in low risk Differentiated Thyroid Cancer (DTC) patients?: Results From the French randomized phase III prospective trial on 776 patients (NCT 01837745)","volume":"5","author":"Leboulleux","year":"2021","journal-title":"J Endocr Soc"},{"issue":"(Suppl 2)","key":"R33-20240828","first-page":"2364","article-title":"[177Lu] Lu-DOTAGA.(SA. FAPi) 2 therapy in advanced stage radioiodine-refractory differentiated thyroid cancer patients","volume":"63","author":"Ballal","year":"2022","journal-title":"J Nucl Med"},{"issue":"(Suppl 2)","key":"R34-20240828","first-page":"3009","article-title":"Lu-177 labeled dimeric RGD peptide in patients with radioiodine refractory-differentiated thyroid cancer:Preliminary experience","volume":"63","author":"Sood","year":"2022","journal-title":"J Nucl Med"},{"key":"R35-20240828","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/cncr.24272","article-title":"[(90) Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer:long-term results of a phase 2 clinical trial","volume":"115","author":"Iten","year":"2009","journal-title":"Cancer"},{"key":"R36-20240828","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/hed.26024","article-title":"Clinical utility of 177 Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity","volume":"42","author":"Parghane","year":"2020","journal-title":"Head Neck"},{"key":"R37-20240828","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ajco.12661","article-title":"Epidemiology of breast cancer in Indian women","volume":"13","author":"Malvia","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"R38-20240828","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1200\/JCO.23.00249","article-title":"Impact of 18F-labeled fluorodeoxyglucose positron emission tomography-computed tomography versus conventional staging in patients with locally advanced breast cancer","volume":"41","author":"Dayes","year":"2023","journal-title":"JCO"},{"key":"R39-20240828","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5603\/NMR.2021.0004","article-title":"Breast cancer and PET imaging","volume":"24","author":"Sarikaya","year":"2021","journal-title":"Nucl Med Rev"},{"key":"R40-20240828","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13058-020-01350-2","article-title":"Prognostic value of 18F-FDG PET and PET\/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer:A systematic review and meta-analysis","volume":"22","author":"Han","year":"2020","journal-title":"Breast Cancer Res"},{"key":"R41-20240828","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MNM.0000000000001515","article-title":"Prediction of pathological response using 18F FDG PET\/CT derived metabolic parameters in locally advanced breast cancer patients","volume":"43","author":"Abd El-Gaid","year":"2022","journal-title":"Nucl Med Commun"},{"key":"R42-20240828","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000524446","article-title":"The role of 18F-FDG PET\/CT in predicting the neoadjuvant treatment response in patients with locally advanced breast cancer","volume":"17","author":"Goktas Aydin","year":"2022","journal-title":"Breast Care"},{"key":"R43-20240828","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.3390\/jcm11071919","article-title":"Head-to-Head comparison between 18F-FES PET\/CT and 18F-FDG PET\/CT in oestrogen receptor-positive breast cancer:A systematic review and meta-analysis","volume":"11","author":"Piccardo","year":"2022","journal-title":"J Clin Med"},{"key":"R44-20240828","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2967\/jnumed.123.265420","article-title":"Summary:Appropriate use criteria for estrogen receptor\u2013targeted PET imaging with 16\u03b1-18F-Fluoro-17\u03b2-Fluoroestradiol","volume":"64","author":"Ulaner","year":"2023","journal-title":"J Nucl Med"},{"key":"R45-20240828","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.7150\/jca.13141","article-title":"Cancer hallmarks, biomarkers and breast cancer molecular subtypes","volume":"7","author":"Dai","year":"2016","journal-title":"J Cancer"},{"key":"R46-20240828","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.annonc.2022.05.006","article-title":"Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer","volume":"33","author":"Baelen","year":"2022","journal-title":"Ann Oncol"},{"key":"R47-20240828","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2214\/AJR.22.28809","article-title":"Prospective pilot study of 18F-Fluoroestradiol PET\/CT in patients with invasive lobular carcinomas","volume":"221","author":"Covington","year":"2023","journal-title":"Am J Roentgenol"},{"key":"R48-20240828","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s12149-021-01672-x","article-title":"Superiority of 68Ga-FAPI PET\/CT scan in detecting additional lesions compared to 18FDG PET\/CT scan in breast cancer","volume":"35","author":"Elboga","year":"2021","journal-title":"Ann Nucl Med"},{"key":"R49-20240828","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J Nucl Med"},{"key":"R50-20240828","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT:Tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"R51-20240828","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s12149-021-01616-5","article-title":"68Ga-FAPI-04 PET\/CT, a new step in breast cancer imaging:A comparative pilot study with the 18F-FDG PET\/CT","volume":"35","author":"K\u00f6mek","year":"2021","journal-title":"Ann Nucl Med"},{"key":"R52-20240828","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s12149-023-01852-x","article-title":"What radiolabeled FAPI pet can add in breast cancer? A systematic review from literature","volume":"37","author":"Evangelista","year":"2023","journal-title":"Ann Nucl Med"},{"key":"R53-20240828","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.3390\/ijms22094597","article-title":"Theranostic advances in breast cancer in nuclear medicine","volume":"22","author":"Vahidfar","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R54-20240828","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1097\/RLU.0000000000003678","article-title":"Theranostic approach in breast cancer:A treasured tailor for future oncology","volume":"46","author":"Jokar","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R55-20240828","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286:First-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J Nucl Med"},{"key":"R56-20240828","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s00259-020-04990-w","article-title":"A theranostic approach of [68Ga]Ga-DOTA. SA. FAPi PET\/CT-guided [177Lu]Lu-DOTA. SA. FAPi radionuclide therapy in an end-stage breast cancer patient:New frontier in targeted radionuclide therapy","volume":"48","author":"Ballal","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R57-20240828","doi-asserted-by":"crossref","first-page":"1250799","DOI":"10.3389\/fmed.2023.1250799","article-title":"GRPR-targeting radiotheranostics for breast cancer management","volume":"10","author":"D'Onofrio","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R58-20240828","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.3390\/jcm9082622","article-title":"Targeted palliative radionuclide therapy for metastatic bone pain","volume":"9","author":"Manafi-Farid","year":"2020","journal-title":"J Clin Med"},{"key":"R59-20240828","doi-asserted-by":"crossref","first-page":"e14813","DOI":"10.1097\/MD.0000000000014813","article-title":"The value of 18F-FDG PET\/CT in the diagnosis of different size of solitary pulmonary nodules","volume":"98","author":"Tang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R60-20240828","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijrobp.2010.09.033","article-title":"A phase II comparative study of gross tumor volume definition with or without PET\/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC):Primary analysis of Radiation Therapy Oncology Group (RTOG) 0515","volume":"82","author":"Bradley","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R61-20240828","doi-asserted-by":"crossref","first-page":"879","DOI":"10.7326\/0003-4819-139-11-200311180-00013","article-title":"Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer:A meta-analysis","volume":"139","author":"Gould","year":"2003","journal-title":"Ann Intern Med"},{"key":"R62-20240828","first-page":"195","article-title":"Positron emission tomography\/computerized tomography in lung cancer","volume":"4","author":"Sahiner","year":"2014","journal-title":"Quant Imaging Med Surg"},{"key":"R63-20240828","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejca.2006.01.026","article-title":"RECIST revisited:A review of validation studies on tumour assessment","volume":"42","author":"Therasse","year":"2006","journal-title":"Eur J Cancer"},{"key":"R64-20240828","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1102\/1470-7330.2011.0036","article-title":"Staging and imaging of small cell lung cancer","volume":"11","author":"Kalemkerian","year":"2011","journal-title":"Cancer Imaging"},{"key":"R65-20240828","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1200\/JCO.2004.11.089","article-title":"Positron emission tomography in limited-stage small-cell lung cancer:A prospective study","volume":"22","author":"Bradley","year":"2004","journal-title":"J Clin Oncol"},{"key":"R66-20240828","first-page":"1911","article-title":"Whole-Body 18F-FDG PET improves the management of patients with small cell lung cancer","volume":"44","author":"Kamel","year":"2003","journal-title":"J Nucl Med"},{"key":"R67-20240828","first-page":"70","article-title":"Evaluation of the role of [18F]FDG-PET\/CT and [68Ga] DOTATOC-PET\/CT in differentiating typical and atypical pulmonary carcinoids","volume":"11","author":"Jindal","year":"2011","journal-title":"Cancer Imaging [Internet"},{"key":"R68-20240828","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1097\/RLU.0000000000000641","article-title":"Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET\/CT for pulmonary carcinoid","volume":"40","author":"Lococo","year":"2015","journal-title":"Clin Nucl Med"},{"key":"R69-20240828","doi-asserted-by":"crossref","first-page":"119","DOI":"10.21037\/acs.2017.03.14","article-title":"8th edition AJCC\/UICC staging of cancers of the esophagus and esophagogastric junction:Application to clinical practice","volume":"6","author":"Rice","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"key":"R70-20240828","first-page":"171","article-title":"Applications of PET-CT in patients with esophageal cancer","volume":"18","author":"Karaosmano\u011flu","year":"2012","journal-title":"Diagn Interv Radiol"},{"key":"R71-20240828","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1148\/rg.292085106","article-title":"Multimodality assessment of esophageal cancer:Preoperative staging and monitoring of response to therapy","volume":"29","author":"Kim","year":"2009","journal-title":"Radiographics"},{"key":"R72-20240828","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2147\/CMAR.S150350","article-title":"Sites of metastasis and overall survival in esophageal cancer:A population-based study","volume":"9","author":"Wu","year":"2017","journal-title":"Cancer Manag Res"},{"key":"R73-20240828","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1097\/JTO.0000000000000006","article-title":"Clinical utility of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in the staging of patients with potentially resectable esophageal cancer","volume":"8","author":"You","year":"2013","journal-title":"J Thorac Oncol"},{"key":"R74-20240828","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1308\/003588414X14055925061270","article-title":"The current role of staging laparoscopy in oesophagogastric cancer","volume":"97","author":"Convie","year":"2015","journal-title":"Ann R Coll Surg Engl"},{"key":"R75-20240828","first-page":"1321","article-title":"Synchronous primary neoplasms detected on 18F-FDG PET in staging of patients with esophageal cancer","volume":"46","author":"van Westreenen","year":"2005","journal-title":"J Nucl Med"},{"key":"R76-20240828","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1200\/JCO.2004.07.122","article-title":"Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment","volume":"22","author":"Wieder","year":"2004","journal-title":"J Clin Oncol"},{"key":"R77-20240828","first-page":"3","article-title":"The role of positron emission tomography in esophageal cancer","volume":"2","author":"Yang","year":"2008","journal-title":"Gastrointest Cancer Res"},{"key":"R78-20240828","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/annonc\/mdf081","article-title":"Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer","volume":"13","author":"Flamen","year":"2002","journal-title":"Ann Oncol"},{"key":"R79-20240828","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1067\/mtc.2000.110464","article-title":"The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer","volume":"120","author":"Flamen","year":"2000","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R80-20240828","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.radonc.2004.10.001","article-title":"Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?","volume":"73","author":"Vrieze","year":"2004","journal-title":"Radiother Oncol"},{"key":"R81-20240828","doi-asserted-by":"crossref","first-page":"875081","DOI":"10.3389\/fonc.2022.875081","article-title":"Comparison of [68Ga] Ga-DOTA-FAPI-04 and [18F]FDG uptake in esophageal cancer","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"R82-20240828","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2021.02.015","article-title":"68Ga-fibroblast activation protein inhibitor PET\/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer","volume":"158","author":"Zhao","year":"2021","journal-title":"Radiother Oncol"},{"key":"R83-20240828","doi-asserted-by":"crossref","first-page":"528","DOI":"10.2967\/jnumed.109.072124","article-title":"Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma:A pilot clinical study","volume":"51","author":"Yue","year":"2010","journal-title":"J Nucl Med"},{"key":"R84-20240828","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40644-021-00391-w","article-title":"Pentixafor PET\/CT for imaging of chemokine receptor 4 expression in esophageal cancer-A first clinical approach","volume":"21","author":"Linde","year":"2021","journal-title":"Cancer Imaging"},{"key":"R85-20240828","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R86-20240828","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1159\/000320277","article-title":"Gastric cancer:Epidemiology and risk factors","volume":"28","author":"Krejs","year":"2010","journal-title":"Dig Dis"},{"key":"R89-20240828","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/j.ejrad.2013.01.021","article-title":"Value of 18F-FDG PET\/CT in the diagnosis of primary gastric cancer via stomach distension","volume":"82","author":"Ma","year":"2013","journal-title":"Eur J Radiol"},{"key":"R90-20240828","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00261-005-0031-3","article-title":"Staging and follow-up of gastrointestinal tumors with PET\/CT","volume":"31","author":"Rosenbaum","year":"2006","journal-title":"Abdom Imaging"},{"key":"R91-20240828","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R92-20240828","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13139-013-0243-3","article-title":"Pretreatment F-18 FDG PET\/CT parameters to evaluate progression-free survival in gastric cancer","volume":"48","author":"Kim","year":"2014","journal-title":"Nucl Med Mol Imaging"},{"key":"R93-20240828","doi-asserted-by":"crossref","first-page":"e864","DOI":"10.1097\/MD.0000000000000864","article-title":"18F-FDG PET\/CT role in staging of gastric carcinomas:Comparison with conventional contrast enhancement computed tomography","volume":"94","author":"Altini","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R94-20240828","doi-asserted-by":"crossref","first-page":"20220437","DOI":"10.1259\/bjr.20220437","article-title":"The impact of baseline 18F-FDG PET-CT on the management and outcome of patients with gastric cancer:A systematic review","volume":"95","author":"Foley","year":"2022","journal-title":"Br J Radiol"},{"key":"R95-20240828","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12149-016-1058-y","article-title":"Fluorine-18-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer after surgical resection:A systematic review and meta-analysis","volume":"30","author":"Li","year":"2016","journal-title":"Ann Nucl Med"},{"key":"R96-20240828","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1186\/s12885-018-4477-4","article-title":"18FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer:Cohort study","volume":"18","author":"Schneider","year":"2018","journal-title":"BMC Cancer"},{"key":"R97-20240828","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40001-023-00997-9","article-title":"[68Ga]Ga-FAPI-04 PET MRI\/CT in the evaluation of gastric carcinomas compared with [18F]-FDG PET MRI\/CT:A meta-analysis","volume":"28","author":"Wang","year":"2023","journal-title":"Eur J Med Res"},{"key":"R98-20240828","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.sult.2012.11.006","article-title":"Positron emission tomography-computed tomography in liver imaging","volume":"34","author":"Sharma","year":"2013","journal-title":"Semin Ultrasound CT MR"},{"key":"R99-20240828","doi-asserted-by":"crossref","first-page":"e105679","DOI":"10.1371\/journal.pone.0105679","article-title":"Does 18F-FDG Positron Emission Tomography-Computed Tomography Have a Role in Initial Staging of Hepatocellular Carcinoma?","volume":"9","author":"Cho","year":"2014","journal-title":"PLoS One"},{"key":"R100-20240828","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.ejrad.2011.08.004","article-title":"18F-FDG PET or PET\/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma:A systematic review and meta-analysis","volume":"81","author":"Lin","year":"2012","journal-title":"Eur J Radiol"},{"key":"R101-20240828","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1478-3231.2006.01296.x","article-title":"Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases:Preliminary findings","volume":"26","author":"Nagaoka","year":"2006","journal-title":"Liver Int"},{"key":"R102-20240828","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1872-034X.2008.00416.x","article-title":"FDG positron emission tomography\/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma","volume":"39","author":"Kawaoka","year":"2009","journal-title":"Hepatol Res"},{"key":"R103-20240828","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1097\/TP.0000000000001297","article-title":"Combination of FDG-PET and UCSF criteria for predicting HCC recurrence after living donor liver transplantation","volume":"100","author":"Hsu","year":"2016","journal-title":"Transplantation"},{"key":"R104-20240828","doi-asserted-by":"crossref","first-page":"693640","DOI":"10.3389\/fonc.2021.693640","article-title":"68Ga-FAPI-04 versus 18F-FDG PET\/CT in the detection of hepatocellular carcinoma","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"R105-20240828","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2967\/jnumed.118.214833","article-title":"68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma:A prospective pilot study","volume":"60","author":"Kesler","year":"2019","journal-title":"J Nucl Med"},{"key":"R106-20240828","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1053\/j.semnuclmed.2019.01.008","article-title":"Holmium-166 microsphere radioembolization of hepatic malignancies","volume":"49","author":"Reinders","year":"2019","journal-title":"Semin Nucl Med"},{"key":"R107-20240828","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrgastro.2013.42","article-title":"Pancreatic cancer:FDG-PET is not useful in early pancreatic cancer diagnosis","volume":"10","author":"Strobel","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R108-20240828","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/s00259-021-05576-w","article-title":"Positron emission tomography and computed tomography with [68Ga] Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer","volume":"49","author":"Pang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R109-20240828","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/14737140.2023.2213890","article-title":"Radiolabeled FAPI in pancreatic cancer:Can it be an additional value in the management of patients?","volume":"23","author":"Evangelista","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"R110-20240828","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3390\/diagnostics12081958","article-title":"FAPI PET versus FDG PET, CT or MRI for staging pancreatic-, gastric- and cholangiocarcinoma:Systematic review and head-to-head comparisons of diagnostic performances","volume":"12","author":"Veldhuijzen van Zanten","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R111-20240828","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.ejso.2020.04.015","article-title":"18-FDG PET-CT should be included in preoperative staging of gall bladder cancer","volume":"46","author":"Goel","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"R112-20240828","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11604-022-01340-8","article-title":"Diagnostic performance of F-18 FDG PET\/CT in recurrent adenocarcinoma gallbladder and its impact on post-recurrence survival","volume":"41","author":"Bedmutha","year":"2023","journal-title":"Jpn J Radiol"},{"key":"R113-20240828","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s12094-015-1434-4","article-title":"SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015","volume":"17","author":"Aranda","year":"2015","journal-title":"Clin Transl Oncol"},{"key":"R114-20240828","first-page":"57","article-title":"FDG PET\/CT in colorectal cancer","volume":"39","author":"Rodr\u00edguez-Fraile","year":"2020","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"R115-20240828","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/MNM.0b013e328357b2d9","article-title":"A systematic review and meta-analysis of pretherapeutic lymph node staging of colorectal cancer by 18F-FDG PET or PET\/CT","volume":"33","author":"Lu","year":"2012","journal-title":"Nucl Med Commun"},{"key":"R116-20240828","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1245\/s10434-012-2300-z","article-title":"Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy:A meta-analysis","volume":"19","author":"van Kessel","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"R117-20240828","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00384-013-1659-z","article-title":"Use of FDG-PET or PET\/CT to detect recurrent colorectal cancer in patients with elevated CEA:A systematic review and meta-analysis","volume":"28","author":"Lu","year":"2013","journal-title":"Int J Colorectal Dis"},{"key":"R118-20240828","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12149-012-0609-0","article-title":"The utility of FDG-PET\/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels","volume":"26","author":"Sanli","year":"2012","journal-title":"Ann Nucl Med"},{"key":"R119-20240828","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/jcm12020577","article-title":"FAPI PET\/CT in diagnostic and treatment management of colorectal cancer:Review of current research status","volume":"12","author":"Cheng","year":"2023","journal-title":"J Clin Med"},{"key":"R120-20240828","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.2967\/jnumed.117.191197","article-title":"68Ga-DOTATOC imaging of neuroendocrine tumors:A systematic review and metaanalysis","volume":"58","author":"Graham","year":"2017","journal-title":"J Nucl Med"},{"key":"R121-20240828","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2967\/jnumed.117.202275","article-title":"Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors","volume":"59","author":"Hope","year":"2018","journal-title":"J Nucl Med"},{"key":"R122-20240828","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0b013e3181ec124e","article-title":"The pathologic classification of neuroendocrine tumors:A review of nomenclature, grading, and staging systems","volume":"39","author":"Klimstra","year":"2010","journal-title":"Pancreas"},{"key":"R123-20240828","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2967\/jnumed.120.244798","article-title":"18F-FDG PET is Superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT:A prospective 10-year follow-up study","volume":"62","author":"Binderup","year":"2021","journal-title":"J Nucl Med"},{"key":"R124-20240828","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.7150\/thno.18068","article-title":"Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours:Proposal for a novel grading scheme with prognostic significance","volume":"7","author":"Chan","year":"2017","journal-title":"Theranostics"},{"key":"R125-20240828","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2967\/jnumed.120.257659","article-title":"Dual PET imaging in bronchial neuroendocrine neoplasms:The NETPET score as a prognostic biomarker","volume":"62","author":"Chan","year":"2021","journal-title":"J Nucl Med"},{"key":"R126-20240828","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"R127-20240828","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/0146645318756253","article-title":"Targeted alpha-particle therapy:Imaging, dosimetry, and radiation protection","volume":"47","author":"Lassmann","year":"2018","journal-title":"Ann ICRP"},{"key":"R128-20240828","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT:First clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R129-20240828","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.clml.2021.03.011","article-title":"Diagnostic performance of pretreatment 18F-fluorodeoxyglucose positron emission tomography with or without computed tomography in patients with primary central nervous system lymphoma:Updated systematic review and diagnostic test accuracy meta-analyses","volume":"21","author":"Gupta","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R130-20240828","doi-asserted-by":"crossref","first-page":"W365","DOI":"10.2214\/AJR.07.2660","article-title":"18F-FDG PET of common enhancing malignant brain tumors","volume":"190","author":"Kosaka","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"R131-20240828","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cpet.2015.03.011","article-title":"18F-flourodeoxy-glucose PET\/computed tomography in brain tumors:Value to patient management and survival outcomes","volume":"10","author":"Wray","year":"2015","journal-title":"PET Clin"},{"key":"R132-20240828","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cpet.2010.02.004","article-title":"PET in brain tumors","volume":"5","author":"Hustinx","year":"2010","journal-title":"PET Clin"},{"key":"R133-20240828","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/MNM.0000000000000753","article-title":"Common malignant brain tumors:Can 18F-FDG PET\/CT aid in differentiation?","volume":"38","author":"Purandare","year":"2017","journal-title":"Nucl Med Commun"},{"key":"R134-20240828","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/RLU.0000000000002006","article-title":"Prediction of overall survival based on isocitrate dehydrogenase 1 mutation and 18F-FDG uptake on PET\/CT in patients with cerebral gliomas","volume":"43","author":"Kim","year":"2018","journal-title":"Clin Nucl Med"},{"key":"R135-20240828","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/MNM.0000000000001449","article-title":"Prognostic significance of 18F-FDG PET\/CT parameters in IDH-1 wild-type GBM and correlation with molecular markers","volume":"42","author":"Dev","year":"2021","journal-title":"Nucl Med Commun"},{"key":"R136-20240828","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/cancers14051103","article-title":"PET imaging in neuro-oncology:An update and overview of a rapidly growing area","volume":"14","author":"Verger","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R137-20240828","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/neuonc\/nov148","article-title":"Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors:Systematic review and meta-analysis","volume":"18","author":"Dunet","year":"2016","journal-title":"Neuro Oncol"},{"key":"R138-20240828","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00259-019-04509-y","article-title":"Integration of dynamic parameters in the analysis of 18F-FDopa PET imaging improves the prediction of molecular features of gliomas","volume":"47","author":"Ginet","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R139-20240828","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00259-017-3846-6","article-title":"Static and dynamic 18F-FET PET for the characterization of gliomas defined by IDH and 1p\/19q status","volume":"45","author":"Verger","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R140-20240828","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2174\/1874471012666190115124536","article-title":"Comparison between 18F-Dopa and 18F-Fet PET\/CT in patients with suspicious recurrent high grade glioma:A literature review and our experience","volume":"12","author":"Evangelista","year":"2019","journal-title":"Curr Radiopharm"},{"key":"R141-20240828","doi-asserted-by":"crossref","first-page":"e1211","DOI":"10.1016\/j.wneu.2018.03.179","article-title":"Accuracy of 18F-FDOPA positron emission tomography and 18F-FET positron emission tomography for differentiating radiation necrosis from brain tumor recurrence","volume":"114","author":"Yu","year":"2018","journal-title":"World Neurosurg"},{"issue":"(6)","key":"R142-20240828","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/jon.12914","article-title":"Brain FET PET tumor-to-white mater ratio to differentiate recurrence from post-treatment changes in high-grade gliomas","volume":"31","author":"Puranik","year":"2021","journal-title":"J Neuroimaging"},{"key":"R143-20240828","doi-asserted-by":"crossref","first-page":"e19017","DOI":"10.1097\/MD.0000000000019017","article-title":"Prognostic value of 18F-FET PET\/CT in newly diagnosed WHO 2016 high-grade glioma","volume":"99","author":"Dissaux","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R144-20240828","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/MNM.0000000000001155","article-title":"Differentiating dural metastases from meningioma:Role of 68Ga DOTA-NOC PET\/CT","volume":"41","author":"Purandare","year":"2020","journal-title":"Nucl Med Commun"},{"key":"R145-20240828","first-page":"1033","article-title":"Positron emission tomography imaging of meningioma in clinic practice review of literature and future directions Neurosurgery","volume":"70","author":"Cornelius","year":"2012"},{"key":"R146-20240828","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.3390\/diagnostics12071666","article-title":"Somatostatin receptor targeted PET-imaging for diagnosis, radiotherapy planning and theranostics of meningiomas:A systematic review of the literature","volume":"12","author":"Filippi","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R147-20240828","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40644-016-0084-2","article-title":"68Ga-DOTATATE and 18F-FDG PET\/CT in paraganglioma and pheochromocytoma:Utility, patterns and heterogeneity","volume":"16","author":"Chang","year":"2016","journal-title":"Cancer Imaging"},{"key":"R148-20240828","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s13139-012-0133-0","article-title":"Ga-68 Somatostatin receptor PET\/CT in von Hippel-Lindau disease","volume":"46","author":"Oh","year":"2012","journal-title":"Nucl Med Mol Imaging"},{"key":"R149-20240828","first-page":"29","article-title":"Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma","volume":"22","author":"Hartrampf","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"R150-20240828","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.3390\/curroncol29080438","article-title":"Somatostatin receptor theranostics for refractory meningiomas","volume":"29","author":"Salgues","year":"2022","journal-title":"Curr Oncol"},{"key":"R151-20240828","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2967\/jnumed.120.249607","article-title":"Somatostatin receptor\u2013targeted radiopeptide therapy in treatment-refractory meningioma:Individual patient data meta-analysis","volume":"62","author":"Mirian","year":"2021","journal-title":"J Nucl Med"},{"key":"R152-20240828","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ejca.2013.11.016","article-title":"A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma","volume":"50","author":"Wilson","year":"2014","journal-title":"Eur J Cancer"},{"key":"R153-20240828","first-page":"357","article-title":"Summary, conclusions, and future directions of [131I] metaiodobenzylguanidine therapy in the treatment of neural crest tumors","volume":"35","author":"Shapiro","year":"1991","journal-title":"J Nucl Biol Med (1991)"},{"key":"R154-20240828","first-page":"649","article-title":"Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma:Systemic review and meta-analysis","volume":"37","author":"Xia","year":"2017","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"R155-20240828","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","article-title":"Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment","volume":"11","author":"Brodeur","year":"1993","journal-title":"J Clin Oncol"},{"key":"R156-20240828","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fmed.2020.00173","article-title":"MIBG therapy for neuroblastoma:Precision achieved with dosimetry, and concern for false responders","volume":"7","author":"Rubio","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"R157-20240828","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1158\/1078-0432.CCR-22-0400","article-title":"Preclinical development of [211At] meta- astatobenzylguanidine ([211At]MABG) as an alpha particle radiopharmaceutical therapy for neuroblastoma","volume":"28","author":"Batra","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"(Suppl 1)","key":"R158-20240828","first-page":"307","article-title":"177Lu-DOTATATE radionuclide therapy for pediatric patients with relapsed high-risk neuroblastoma negative on 131I-MIBG imaging-A pilot study","volume":"59","author":"Chen","year":"2018","journal-title":"J Nucl Med"},{"key":"R159-20240828","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s00259-017-3829-7","article-title":"Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations:The SIOPEN\/HR-NBL1 and COG-A3973 trials","volume":"45","author":"Ladenstein","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R160-20240828","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2967\/jnumed.117.195883","article-title":"Validation of postinduction curie scores in high-risk neuroblastoma:A children's oncology group and SIOPEN group report on SIOPEN\/HR-NBL1","volume":"59","author":"Yanik","year":"2018","journal-title":"J Nucl Med"},{"key":"R161-20240828","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2967\/jnumed.112.112334","article-title":"Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma:A report from the Children's oncology group","volume":"54","author":"Yanik","year":"2013","journal-title":"J Nucl Med"},{"key":"R162-20240828","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s00259-022-06063-6","article-title":"[18F]mFBG PET-CT for detection and localisation of neuroblastoma:A prospective pilot study","volume":"50","author":"Samim","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R163-20240828","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/jpm11040270","article-title":"Nuclear medicine imaging in neuroblastoma:Current status and new developments","volume":"11","author":"Samim","year":"2021","journal-title":"J Pers Med"},{"key":"R164-20240828","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s00247-023-05596-8","article-title":"Imaging in rhabdomyosarcoma:A patient journey","volume":"53","author":"de Vries","year":"2023","journal-title":"Pediatr Radiol"},{"key":"R165-20240828","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2967\/jnumed.120.254110","article-title":"SNMMI procedure standard\/EANM practice guideline on pediatric 18F-FDG PET\/CT for oncology 1.0","volume":"62","author":"Vali","year":"2021","journal-title":"J Nucl Med"},{"key":"R166-20240828","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.ejso.2022.03.001","article-title":"In transit metastases in children, adolescents and young adults with localized rhabdomyosarcoma of the distal extremities:Analysis of the EpSSG RMS 2005 study","volume":"48","author":"Terwisscha van Scheltinga","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"R167-20240828","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MNM.0000000000001491","article-title":"FDG PETCT for assessing marrow involvement at staging pediatric nonhematological round cell malignancies","volume":"43","author":"Shah","year":"2022","journal-title":"Nucl Med Commun"},{"key":"R168-20240828","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.semnuclmed.2022.10.001","article-title":"Overview and recent advances in 18F-FDG PET\/CT for evaluation of pediatric lymphoma","volume":"53","author":"Guja","year":"2023","journal-title":"Semin Nucl Med"},{"key":"R169-20240828","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1148\/radiol.11110936","article-title":"Pediatric nonlymphoblastic non-Hodgkin lymphoma:Baseline, interim, and posttreatment PET\/CT versus contrast-enhanced CT for evaluation--A prospective study","volume":"262","author":"Bakhshi","year":"2012","journal-title":"Radiology"},{"key":"R170-20240828","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.urology.2014.06.010","article-title":"Toward better use of bone scans among men with early-stage prostate cancer","volume":"84","author":"Merdan","year":"2014","journal-title":"Urology"},{"key":"R171-20240828","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","article-title":"Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer:Exploratory analyses by baseline prostate-specific antigen doubling time","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"R172-20240828","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA):A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"R173-20240828","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer:A prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"R174-20240828","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1053\/j.semnuclmed.2019.02.001","article-title":"New targets for PET molecular imaging of prostate cancer","volume":"49","author":"Mena","year":"2019","journal-title":"Semin Nucl Med"},{"key":"R175-20240828","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy:A prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol"},{"key":"R176-20240828","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1148\/radiol.2020191689","article-title":"PSMA-targeted radiotracers versus 18F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy:A systematic review and meta-analysis","volume":"296","author":"Tan","year":"2020","journal-title":"Radiology"},{"key":"R177-20240828","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1102\/1470-7330.2012.0042","article-title":"Meta-analysis of the diagnostic performance of [18F] FDG-PET and PET\/CT in renal cell carcinoma","volume":"12","author":"Wang","year":"2012","journal-title":"Cancer Imaging"},{"key":"R178-20240828","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1464-410X.2008.08150.x","article-title":"Significance of 18F-fluorodeoxyglucose positron-emission tomography\/computed tomography for the postoperative surveillance of advanced renal cell carcinoma","volume":"103","author":"Park","year":"2009","journal-title":"BJU Int"},{"key":"R179-20240828","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.semnuclmed.2005.09.001","article-title":"Nuclear medicine studies of the prostate, testes, and bladder","volume":"36","author":"Jana","year":"2006","journal-title":"Semin Nucl Med"},{"key":"R180-20240828","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1200\/JCO.2010.28.7052","article-title":"Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography in bladder cancer","volume":"28","author":"Apolo","year":"2010","journal-title":"J Clin Oncol"},{"key":"R181-20240828","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1007\/s00259-005-1886-9","article-title":"FDG-PET for preoperative staging of bladder cancer","volume":"32","author":"Drieskens","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R182-20240828","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/RLU.0b013e318238f6ea","article-title":"Accuracy of 18F-FDG PET\/CT for diagnosing inguinal lymph node involvement in penile squamous cell carcinoma:Systematic review and meta-analysis of the literature","volume":"37","author":"Sadeghi","year":"2012","journal-title":"Clin Nucl Med"},{"key":"R183-20240828","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejrad.2004.07.012","article-title":"FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals","volume":"54","author":"Becherer","year":"2005","journal-title":"Eur J Radiol"},{"key":"R184-20240828","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.2967\/jnumed.119.235333","article-title":"68Ga-PSMA PET\/CT combined with PET\/ultrasound-guided prostate biopsy can diagnose clinically significant prostate cancer in men with previous negative biopsy results","volume":"61","author":"Liu","year":"2020","journal-title":"J Nucl Med"},{"key":"R185-20240828","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00259-020-04863-2","article-title":"68Ga-PSMA PET\/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy:A prospective randomized single-centre study","volume":"48","author":"Zhang","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R186-20240828","first-page":"1644","article-title":"The PRIMARY score:Using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"issue":"(6 Suppl)","key":"R187-20240828","doi-asserted-by":"crossref","first-page":"TPS397","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS397","article-title":"PRIMARY2:A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [68Ga] Ga-PSMA-11 PET\/CT in men with negative\/equivocal MRI in the diagnosis of clinically significant prostate cancer","volume":"41","author":"Buteau","year":"2023","journal-title":"J Clin Oncol"},{"key":"R188-20240828","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2967\/jnumed.119.233817","article-title":"Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging:The PSMA PET progression criteria","volume":"61","author":"Fanti","year":"2020","journal-title":"J Nucl Med"},{"key":"R189-20240828","doi-asserted-by":"crossref","first-page":"e222148","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology"},{"issue":"(6 Suppl)","key":"R190-20240828","doi-asserted-by":"crossref","first-page":"LBA602","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA602","article-title":"Results from phase 3 study of 89Zr-DFO-girentuximab for PET\/CT imaging of clear cell renal cell carcinoma (ZIRCON)","volume":"41","author":"Shuch","year":"2023","journal-title":"J Clin Oncol"},{"key":"R191-20240828","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1158\/1078-0432.CCR-22-1547","article-title":"ImmunoPET imaging with 89Zr-labeled atezolizumab enables in vivo evaluation of PD-L1 in tumorgraft models of renal cell carcinoma","volume":"28","author":"Mulgaonkar","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R192-20240828","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.urology.2007.03.025","article-title":"Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms","volume":"70","author":"Baccala","year":"2007","journal-title":"Urology"},{"key":"R193-20240828","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1007\/s00259-019-04432-2","article-title":"The use of 68Ga-PET\/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma","volume":"46","author":"Raveenthiran","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R194-20240828","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2967\/jnumed.114.144840","article-title":"89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment","volume":"56","author":"Oosting","year":"2015","journal-title":"J Nucl Med"},{"key":"R195-20240828","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"R196-20240828","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP):A randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"R197-20240828","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP):Secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"R198-20240828","doi-asserted-by":"crossref","first-page":"S1324","DOI":"10.1016\/j.annonc.2023.10.085","article-title":"LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)","volume":"34","author":"Sartor","year":"2023","journal-title":"Ann Oncol"},{"key":"R199-20240828","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter Radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"R200-20240828","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act):A multicentre, retrospective study","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol"},{"key":"R201-20240828","article-title":"PET\/CT in Non-Hodgkin Lymphoma","author":"Agrawal","year":"2021","journal-title":"Springer Nature"},{"key":"R202-20240828","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2967\/jnumed.116.184218","article-title":"Prognostic value of bone marrow tracer uptake pattern in baseline PET scans in Hodgkin lymphoma:Results from an International Collaborative Study","volume":"58","author":"Zwarthoed","year":"2017","journal-title":"J Nucl Med"},{"key":"R203-20240828","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma:The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"R204-20240828","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT Scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"R205-20240828","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.semnuclmed.2017.09.002","article-title":"Interim FDG-PET imaging in lymphoma","volume":"48","author":"Gallamini","year":"2018","journal-title":"Semin Nucl Med"},{"key":"R206-20240828","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL):A multicenter, randomized phase III trial","volume":"36","author":"D\u00fchrsen","year":"2018","journal-title":"J Clin Oncol"},{"issue":"(Suppl 2)","key":"R207-20240828","first-page":"2719","article-title":"The role of FDG-PET in assessing response to CAR-T cell therapy","volume":"63","author":"Glennan","year":"2022","journal-title":"J Nucl Med"},{"key":"R208-20240828","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","article-title":"Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma","volume":"125","author":"Sauter","year":"2015","journal-title":"Blood"},{"key":"R209-20240828","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.ijrobp.2022.07.489","article-title":"18FDG PET\/CT parameters for the prediction of CAR T-cell therapy response among patients with large B-cell lymphoma","volume":"114","author":"Ababneh","year":"2022","journal-title":"Int J Radiation Oncol Biol Physics"},{"key":"R210-20240828","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2967\/jnumed.122.265199","article-title":"Theranostics in hematooncology","volume":"64","author":"Buck","year":"2023","journal-title":"J Nucl Med"},{"issue":"(Suppl)","key":"R211-20240828","doi-asserted-by":"crossref","first-page":"e2941723","DOI":"10.1097\/01.HS9.0000967904.29417.23","article-title":"S248:SIERRA trial results with a targeted radiotherapy, IOMAB-B, a myeloablative conditioning with reduced intensity tolerability yields high CR, long term survival in HSCT ineligible active R\/R AML","volume":"7","author":"Gyurkocza","year":"2023","journal-title":"Hemasphere"},{"key":"R212-20240828","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"key":"R213-20240828","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders:A consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"key":"R214-20240828","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"R215-20240828","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"R216-20240828","doi-asserted-by":"crossref","first-page":"20211272","DOI":"10.1259\/bjr.20211272","article-title":"Imaging CXCR4 receptors expression for staging multiple myeloma by using 68Ga-Pentixafor PET\/CT:Comparison with 18F-FDG PET\/CT","volume":"95","author":"Shekhawat","year":"2022","journal-title":"Br J Radiol"},{"key":"R217-20240828","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","article-title":"Chemokine receptor-4 targeted PET\/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma:Comparison to 18F-FDG PET\/CT","volume":"47","author":"Pan","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R218-20240828","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s12149-021-01652-1","article-title":"Prognostic significance of 68Ga-Pentixafor PET\/CT in multiple myeloma recurrence:A comparison to 18F-FDG PET\/CT and laboratory results","volume":"35","author":"Kuyumcu","year":"2021","journal-title":"Ann Nucl Med"},{"key":"R219-20240828","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2967\/jnumed.118.223420","article-title":"Side effects of CXC-chemokine receptor 4-directed endoradiotherapy with pentixather before hematopoietic stem cell transplantation","volume":"60","author":"Maurer","year":"2019","journal-title":"J Nucl Med"},{"key":"R220-20240828","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"R221-20240828","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.3390\/cancers14225528","article-title":"Recent imaging updates and advances in gynecologic malignancies","volume":"14","author":"Daoud","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R222-20240828","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/curroncol30010083","article-title":"Current update on PET\/MRI in gynecological malignancies-A review of the literature","volume":"30","author":"Virarkar","year":"2023","journal-title":"Curr Oncol"},{"key":"R223-20240828","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12885-018-4498-z","article-title":"Changes in ovarian cancer survival during the 20 years before the era of targeted therapy","volume":"18","author":"Lee","year":"2018","journal-title":"BMC Cancer"},{"key":"R224-20240828","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1007\/s00261-017-1441-8","article-title":"The role of FDG-PET\/CT in gynecologic imaging:An updated guide to interpretation and challenges","volume":"43","author":"Akin","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"R225-20240828","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/jimaging9100223","article-title":"18F-FDG PET\/MRI and 18F-FDG PET\/CT for the management of gynecological malignancies:A comprehensive review of the literature","volume":"9","author":"Allahqoli","year":"2023","journal-title":"J Imaging"},{"key":"R226-20240828","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2214\/ajr.182.1.1820227","article-title":"Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer","volume":"182","author":"Yoshida","year":"2004","journal-title":"AJR Am J Roentgenol"},{"key":"R227-20240828","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.suronc.2017.07.004","article-title":"The role of F18-FDG PET\/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer","volume":"26","author":"Amit","year":"2017","journal-title":"Surg Oncol"},{"key":"R228-20240828","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.ejrad.2011.01.112","article-title":"Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography\/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer:A meta-analysis","volume":"81","author":"Yuan","year":"2012","journal-title":"Eur J Radiol"},{"key":"R229-20240828","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s00259-018-3961-z","article-title":"18F-FDG-PET\/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer","volume":"45","author":"Vallius","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R230-20240828","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2015.10.018","article-title":"18F-FDG-PET\/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer","volume":"140","author":"Vallius","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R231-20240828","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.6004\/jnccn.2023.0062","article-title":"NCCN Guidelines\u00ae insights:Cervical cancer, Version 1.2024","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"R232-20240828","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ygyno.2004.12.007","article-title":"FDG-PET for management of cervical and ovarian cancer","volume":"97","author":"Havrilesky","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R233-20240828","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ygyno.2017.12.003","article-title":"Impact of para-aortic recurrence risk-guided intensity-modulated radiotherapy in locally advanced cervical cancer with positive pelvic lymph nodes","volume":"148","author":"Lee","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R234-20240828","doi-asserted-by":"crossref","first-page":"8874990","DOI":"10.1155\/2021\/8874990","article-title":"Diagnostic accuracy of 18F-FDG-PET\/CT and MRI in predicting the tumor response in locally advanced cervical carcinoma treated by chemoradiotherapy:A meta-analysis","volume":"2021","author":"Sanei Sistani","year":"2021","journal-title":"Contrast Media Mol Imaging"},{"key":"R235-20240828","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.2214\/AJR.18.19734","article-title":"Prognostic value of volume-based metabolic parameters of 18F-FDG PET\/CT in uterine cervical cancer:A systematic review and meta-analysis","volume":"211","author":"Han","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"R236-20240828","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer:2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"R237-20240828","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/0971-3026.155857","article-title":"Imaging in endometrial carcinoma","volume":"25","author":"Faria","year":"2015","journal-title":"Indian J Radiol Imaging"},{"key":"R238-20240828","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2967\/jnumed.115.170597","article-title":"High diagnostic value of 18F-FDG PET\/CT in endometrial cancer:Systematic review and meta-analysis of the literature","volume":"57","author":"Bollineni","year":"2016","journal-title":"J Nucl Med"},{"key":"R239-20240828","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3349\/ymj.2014.55.6.1467","article-title":"Role of 18F-FDG PET\/CT in the carcinoma of the uterus:A review of literature","volume":"55","author":"Musto","year":"2014","journal-title":"Yonsei Med J"},{"key":"R240-20240828","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/RLU.0b013e31824d24fa","article-title":"Carcinoma endometrium:Role of 18-FDG PET\/CT for detection of suspected recurrence","volume":"37","author":"Sharma","year":"2012","journal-title":"Clin Nucl Med"},{"key":"R241-20240828","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1007\/s00259-021-05378-0","article-title":"68Ga-FAPI-PET\/CT in patients with various gynecological malignancies","volume":"48","author":"Dendl","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R242-20240828","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.5114\/pjr.2020.98686","article-title":"Revisiting the WHO classification system of bone tumours:Emphasis on advanced magnetic resonance imaging sequences. Part 2","volume":"85","author":"Ahlawat","year":"2020","journal-title":"Pol J Radiol."},{"key":"R243-20240828","doi-asserted-by":"crossref","first-page":"W521","DOI":"10.2214\/AJR.13.11833","article-title":"FDG PET\/CT of primary bone tumors","volume":"202","author":"Costelloe","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"R244-20240828","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00256-019-03192-2","article-title":"18F-FDG PET-CT versus MRI for detection of skeletal metastasis in Ewing sarcoma","volume":"48","author":"Bosma","year":"2019","journal-title":"Skeletal Radiol"},{"key":"R245-20240828","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/RLU.0b013e3182817af3","article-title":"Comparison of FDG PET\/CT and gadolinium-enhanced MRI for the detection of bone metastases in patients with cancer","volume":"38","author":"Duo","year":"2013","journal-title":"Clin Nucl Med"},{"key":"R246-20240828","first-page":"1186","article-title":"[Update and interpretation of 2021 National Comprehensive Cancer Network (NCCN) 'Clinical Practice Guidelines for Bone Tumors'","volume":"35","author":"Ni","year":"2021","journal-title":"Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi"},{"key":"R247-20240828","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1159\/000505651","article-title":"Meta-analysis of the diagnostic accuracy of primary bone and soft tissue sarcomas by 18F-FDG-PET","volume":"29","author":"Younis","year":"2020","journal-title":"Med Princ Pract"},{"key":"R248-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2019.07.002","article-title":"Utility of positron emission tomography\/computed tomography (PET\/CT) imaging in the evaluation of sarcomas:A systematic review","volume":"143","author":"Lim","year":"2019","journal-title":"Clin Rev Oncol Hematol"},{"key":"R250-20240828","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12885-019-5488-5","article-title":"Effectiveness of 18F-FDG PET\/CT in the diagnosis and staging of osteosarcoma:A meta-analysis of 26 studies","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Cancer"},{"key":"R251-20240828","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2214\/AJR.14.12932","article-title":"Pediatric bone sarcoma:Diagnostic performance of 18F-FDG PET\/CT versus conventional imaging for initial staging and follow-up","volume":"204","author":"Quartuccio","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"R252-20240828","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s002590000301","article-title":"FDG-PET for detection of osseous metastases from malignant primary bone tumours:Comparison with bone scintigraphy","volume":"27","author":"Franzius","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"R253-20240828","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/pbc.26014","article-title":"Comparison of 18F-FDG-PET-CT and bone scintigraphy for evaluation of osseous metastases in newly diagnosed and recurrent osteosarcoma","volume":"63","author":"Hurley","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R254-20240828","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1097\/CORR.0000000000001681","article-title":"What Is the comparative ability of 18F-FDG PET\/CT, 99mTc-MDP skeletal scintigraphy, and whole-body MRI as a staging investigation to detect skeletal metastases in patients with osteosarcoma and Ewing sarcoma?","volume":"479","author":"Aryal","year":"2021","journal-title":"Clin Orthop Relat Res"},{"key":"R255-20240828","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/pbc.24406","article-title":"An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration\/biopsy as staging investigations in Ewing sarcoma","volume":"60","author":"Newman","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R256-20240828","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/j.suronc.2012.07.002","article-title":"18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas:A meta-analysis","volume":"21","author":"Hongtao","year":"2012","journal-title":"Surg Oncol"},{"key":"R257-20240828","first-page":"1508","article-title":"Noninvasive grading of musculoskeletal tumors using PET","volume":"32","author":"Adler","year":"1991","journal-title":"J Nucl Med"},{"key":"R258-20240828","first-page":"717","article-title":"18F-FDG PET for the Diagnosis and Grading of Soft-Tissue Sarcoma:A Meta-Analysis |","volume":"44","author":"Ioannidis","year":"2003","journal-title":"J Nucl Med"},{"key":"R259-20240828","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13569-018-0095-9","article-title":"Retrospective audit of 957 consecutive 18F-FDG PET\u2013CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma","volume":"8","author":"Macpherson","year":"2018","journal-title":"Clin Sarcoma Res"},{"key":"R260-20240828","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2214\/AJR.11.7560","article-title":"Correlating metabolic activity on 18F-FDG PET\/CT with histopathologic characteristics of osseous and soft-tissue sarcomas:A retrospective review of 136 patients","volume":"198","author":"Rakheja","year":"2012","journal-title":"Am J Roentgenol"},{"key":"R261-20240828","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa012782","article-title":"A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer","author":"Veronesi","year":"2003","journal-title":"N. Engl. J. Med"},{"key":"R262-20240828","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival among Women with Invasive Breast Cancer and Sentinel Node Metastasis:The ACOSOG Z0011 (Alliance) Randomized Clinical Trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA-J. Am. Med. Assoc"},{"key":"R263-20240828","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-Lymph-Node Biopsy in Patients with Breast Cancer before and after Neoadjuvant Chemotherapy (SENTINA):A Prospective, Multicentre Cohort Study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"R264-20240828","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/jpm11030172","article-title":"Sentinel Node Biopsy after Neoadjuvant Chemotherapy for Breast Cancer:Preliminary Experience with Clinically Node Negative Patients after Systemic Treatment","volume":"11","author":"Sanchez","year":"2021","journal-title":"J Pers Med"},{"key":"R265-20240828","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcms.2023.12.012","article-title":"Sentinel lymph node biopsy versus elective neck dissection in management of the clinically negative (cN0) neck in patients with oral squamous cell carcinoma:A systematic review and meta-analysis","volume":"52","author":"Al-Moraissi","year":"2024","journal-title":"J Craniomaxillofac Surg"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.ijc_52_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:23:40Z","timestamp":1787768620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.ijc_52_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":262,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_52_24","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2024-01-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}